The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
Belantamab Mafodotin Blenrep®
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
SEA-BCMA
SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
Belantamab Mafodotin Blenrep®
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
ABBV-383
ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.
Belantamab Mafodotin Blenrep®
Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).
SEA-BCMA
SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant
IDE-CEL POST HEMATOPOIETIC CELL TRANSPLANT
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPY
SparkCures Verified Accurate, up-to-date information. Learn more
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
BELANTAMAB MAFODOTIN IN THE COMMUNITY SETTINGA Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multipl...
ELRANATAMAB AS CONSOLIDATIONA Phase Ib Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A...
BCMA CAR-T CELL INJECTION (CT103A)A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide ...
CAR-T FOR PATIENTS WITH RENAL IMPAIRMENTBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
BELANTAMAB MAFODOTIN COMBINATION THERAPYExpanded Access Request Program for Belantamab Mafodotin in Multiple Myeloma
EXPANDED ACCESS REQUEST FOR BELANTAMAB MAFODOTINFeasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antige...
AUTOLOGOUS STEM CELL TRANSPLANT POST CAR-TMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
MRD-GUIDED ELRANATAMAB MAINTENANCE THERAPYMinimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autolo...
BELANTAMAB MAFODOTIN OR LENALIDOMIDE MAINTENANCEMMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
HORIZON ADAPTIVE PLATFORMNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
BELANTAMAB MAFODOTIN AND ELOTUZUMABPhase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATIONPhase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Patients With Relapsed and/or Refractory ...
BCMA-TGF-BETA INSENSITIVE ARMORED CAR T CELLSPhase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Cla...
DIFFERENT DOSES OF BELANTAMAB MAFODOTINPre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With...
PRE AND POST TRANSPLANT ELRANATAMABProvide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
LINVOSELTAMAB - COMPASSIONATE USEThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
SparkCures Verified Accurate, up-to-date information. Learn more
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
MRD-GUIDED ELRANATAMAB MAINTENANCE THERAPYMinimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autolo...
BELANTAMAB MAFODOTIN OR LENALIDOMIDE MAINTENANCEPhase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATIONPre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With...
PRE AND POST TRANSPLANT ELRANATAMABThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Phase Ib Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A...
BCMA CAR-T CELL INJECTION (CT103A)Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antige...
AUTOLOGOUS STEM CELL TRANSPLANT POST CAR-TPhase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATIONThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant
IDE-CEL POST HEMATOPOIETIC CELL TRANSPLANT
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
BELANTAMAB MAFADOTIN MAINTENANCE THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
BELANTAMAB MAFODOTIN IN THE COMMUNITY SETTINGA Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multipl...
ELRANATAMAB AS CONSOLIDATIONA Phase Ib Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A...
BCMA CAR-T CELL INJECTION (CT103A)Expanded Access Request Program for Belantamab Mafodotin in Multiple Myeloma
EXPANDED ACCESS REQUEST FOR BELANTAMAB MAFODOTINFeasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antige...
AUTOLOGOUS STEM CELL TRANSPLANT POST CAR-TNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
BELANTAMAB MAFODOTIN AND ELOTUZUMABPhase 2 Trial of Belantamab Mafodotin Consolidation Treatment in Patients With Multiple Myeloma and MRD Pos...
BELANTAMAB MAFODOTIN CONSOLIDATIONPhase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Patients With Relapsed and/or Refractory ...
BCMA-TGF-BETA INSENSITIVE ARMORED CAR T CELLSPhase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Cla...
DIFFERENT DOSES OF BELANTAMAB MAFODOTINThe following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The following is a listing of myeloma tags that are associated with this tag.
Antibody Drug Conjugate (ADC)
Antibody Drug Conjugates (ADC) work by combining a chemotherapy drug with a monoclonal antibody. This allows the chemotherapy drug to target a specific cancer cell while limiting the damage to healthy cells.
Bispecific Antibody
A bispecific antibody is a drug that has been designed to simultaneously target two different proteins. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells.
CAR T Cell
CAR T Cell therapy is a new way to treat multiple myeloma using your own immune system to target and destroy cancer cells.
Monoclonal Antibody
Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.